Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Additional Locations, Illinois Clinical Trials

A listing of Additional Locations, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (1858) clinical trials

Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease

Chronic Graft versus Host Disease (GVHD) is an important cause of morbidity and mortality in patients undergoing allogeneic bone marrow and hematopoietic progenitor cell transplantation. In adults, it has been shown that patients with acute or chronic GVHD have an increase in their resting energy expenditure (REE), likely as a ...

Phase N/A

0.68 miles

Learn More »

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants Children and Adolescents

DTG is an HIV medicine in the integrase inhibitor drug class. The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of DTG in HIV-1 infected infants, children, and adolescents. Participation in this study will last approximately 48 weeks, followed by long-term safety follow-up that ...

Phase

0.68 miles

Learn More »

Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission

The purpose of this study is to explore the effects of early intensive antiretroviral therapy (ART) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among HIV-infected infants. The study will enroll two cohorts. Cohort 1 will include infants at high risk for in utero ...

Phase

0.68 miles

Learn More »

Patients are needed to participate in a clinical research study to evaluate LIVER DISEASE

All the new pediatric participants will have had a liver biopsy within 120 days prior to enrollment coupled with contemporaneous biosamples within 90 days prior to enrollment and up to 90 days before or 4-90 days after the biopsy. We estimate that at least 50 of the continuing pediatric participants ...

Phase N/A

0.68 miles

Learn More »

Evaluating the Safety and Pharmacokinetics of VRC01 VRC01LS and VRC07-523LS Potent Anti-HIV Neutralizing Monoclonal Antibodies in HIV-1-Exposed Infants

VRC01, VRC01LS, and VRC07-523LS are anti-HIV neutralizing monoclonal antibodies that may help prevent mother-to-child transmission of HIV. This study will enroll HIV-infected mothers who are at increased risk of passing HIV on to their children. The purpose of this study is to assess the safety and PK of VRC01, VRC01LS, ...

Phase

0.68 miles

Learn More »

Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood

Ensuring the safety and comfort of the more than 100,000 critically ill infants and young children supported on mechanical ventilation in the US each year is integral to the practice of pediatric critical care. Humane care of these young patients requires the use of sedating medications, most commonly combinations of ...

Phase N/A

0.68 miles

Learn More »

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

The purpose of this study is to understand if the study drugs of interest are found in breastmilk and how much; to estimate the amount of drug that is consumed by breastfed infants and what effect this may have on infants; and to share what we learn with other researchers. ...

Phase N/A

0.68 miles

Learn More »

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Pregnant women experience unique physiological changes that may result in clinically significant alterations in drug PKs. Unfortunately, there have been few clinical trials to study the PKs of ARV, TB, and hormonal contraceptive drugs in pregnant women. The development of appropriate dosing regimens for the HIV-infected pregnant woman is critical ...

Phase

0.68 miles

Learn More »

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

Maraviroc is a CCR5 receptor antagonist used to treat HIV infection in adults. Adding maraviroc to a standard of care prophylaxis regimen may also reduce the risk of perinatal transmission of HIV. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of maraviroc in HIV-1-exposed infants ...

Phase

0.68 miles

Learn More »

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

This study will confirm the dose and evaluate the safety, acceptability, tolerability, and pharmacokinetics (PK) of oral cabotegravir (CAB), long-acting injectable cabotegravir (CAB LA), and long-acting injectable rilpivirine (RPV LA) in virologically suppressed HIV1 infected children and adolescents aged 12 to less than 18 years. The study will include two ...

Phase

0.68 miles

Learn More »